Soki Kashima (@KashimaMDPhD) header
Soki Kashima (@KashimaMDPhD) profile picture

Soki Kashima

@KashimaMDPhD

Urologist, Surgeon-scientist, Immune-oncology, Kidney cancer, Associate Research Scientist, Faculty @YaleMed @YaleCancer https://nitter.gq/t.co/fiYnlM7kWl

 New Haven, CT
Joined September 2022
  • Tweets267
  • Following344
  • Followers231
25Media
Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)Photo by Soki Kashima (@KashimaMDPhD)
I thrilled to share our review and Beyond the Abstract on “The Changing Landscape of Immunotherapy for Advanced Renal Cancer” from sciencedirect.com/science/ar… and urotoday.com/recent-abstract… I really appreciate @BraunMDPhD's mentoring @UroToday @YaleCancer @YaleMed @UrologicClinics
Image from Soki Kashima (@KashimaMDPhD)
UroToday.com (@urotoday) profile pictureUroToday.com
@urotoday24 Jul 2023
The changing landscape of immunotherapy for advanced #RenalCancer. #BeyondTheAbstract with @KashimaMDPhD and @BraunMDPhD @YaleCancer. #ReadNow on UroToday > bit.ly/3CPrXmY @YaleMed @UrologicClinics
Image from UroToday.com (@urotoday)
1
9
3
26
10,230
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer. ⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy. 🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it. #BladderCancer #GUOnc @OncoAlert @BladderCancerUS
Image from David H Aggen, MD PhD (@Dr_Aggen)
4
61
1
118
10,588
Soki Kashima retweeted
Toni Choueiri, MD (@DrChoueiri) profile picture
Toni Choueiri, MD
@DrChoueiriOct 25
Why is ADC development in RCC challenging?Great overview by @YujiMiura5 highlighting 3 barriers: Delivery: heterogeneous vasculature limits ADC penetration. Targeting: antigen heterogeneity & vascular trapping. Payload: efficacy vs toxicity Time to rethink targets & payloads! @myESMO @oncoalert #ESMO26
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
2
25
1
56
4,258
Everyone should listen to a @BraunMDPhD talk at least quarterly (doctor's orders!) Fantastic talk focused on personalized cancer vaccines in RCC. Looking forward to the results of INTerpath-004! #ESMO26 @OncoAlert
Image from Renee Maria Saliby (@ReneeSaliby)
Image from Renee Maria Saliby (@ReneeSaliby)
Image from Renee Maria Saliby (@ReneeSaliby)
Image from Renee Maria Saliby (@ReneeSaliby)
17
1
37
1,382
Great talk by @BradMcG04 at the JSCO–ASCO Joint Session @official_jsco on perioperative therapy for RCC Adjuvant therapy is evolving rapidly, but identifying who truly benefits remains a key challenge. Exciting potential for biomarkers like KIM-1! #JSCO2026 #RCC #KidneyCancer
Image from Soki Kashima (@KashimaMDPhD)
3
1
8
2,467
Soki Kashima retweeted
Toni Choueiri, MD (@DrChoueiri) profile picture
Toni Choueiri, MD
@DrChoueiriOct 10
New @jclinicalinvest study led by @BraunMDPhD @YaleCancer and super star Dr Madsen : HIF-2α inhibition with belzutifan preserves T-cell effector function in ccRCC—supporting the rationale for combining HIF-2α and PD-1 blockade without compromising T-cell activity. Reassuring translational evidence! jci.org/articles/view/204613
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
6
29
2
82
6,605
Soki Kashima retweeted
Toni Choueiri, MD (@DrChoueiri) profile picture
Toni Choueiri, MD
@DrChoueiriSep 30
Congratulations to @romeerizwan and team on this exciting work in @CD_AACR —a terrific collaboration (that includes our @DanaFarber_GU group) on spatially confined IL-12 + CAR-NK biology. And a very pleasant surprise on the same page: seeing @BraunMDPhD, now at @YaleCancer featured as the 2026 Cancer Discovery Journal Awardee. Full-circle moment! @DanaFarber @DanaFarberNews @harvardmed
Image from Toni Choueiri, MD (@DrChoueiri)
Cancer Discovery (@CD_AACR) profile pictureCancer Discovery@CD_AACRSep 30
Now online: Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks doi.org/10.1158/2159-8290.CD…
Image from Cancer Discovery (@CD_AACR)
2
9
1
29
5,397
ARiSE採択課題一覧 jst.go.jp/pr/info/info1875/p… やはりデジタルツインは世間の期待が大きい。 基盤モデル作りも大事。 実用化やインフラ化の道筋は課題になりそう。
2
99
Soki Kashima retweeted
Brian Rini, MD (@brian_rini) profile picture
Brian Rini, MD@brian_riniSep 19
The Academy of Kidney Cancer Investigators is a DOD-funded mentoring Academy of the next generation of RCC leaders. Our monthly didactic lectures on RCC topics from leaders in the field is available here: youtube.com/@AcademyofKidney…
Academy of Kidney Cancer Investigators AKCI

Academy of Kidney Cancer Investigators AKCI

youtube.com
10
42
4,389
Soki Kashima retweeted
Tom Powles (@tompowles1) profile picture
Tom Powles
@tompowles1Sep 25
FDA grants Priority Review for the VOLGA trail, in which 3 neoadjuvant cycles of EV and a year of Perioperative durvalumab was given for patients with muscle invasive bladder cancer. Press release states an EFS and OS advantage. Data will be presented #ESMO26 @OncoAlert @myESMO @Annals_Oncology astrazeneca-us.com/content/a…
Image from Tom Powles (@tompowles1)
7
61
4
132
13,528
Soki Kashima retweeted
Toni Choueiri, MD (@DrChoueiri) profile picture
Toni Choueiri, MD
@DrChoueiriSep 27
My picks in #GU Oncology for #ESMO2026. Exciting new data to be presented @myESMO !
Image from Toni Choueiri, MD (@DrChoueiri)
4
88
5
176
14,885
JUA2027の26人目フォロワーにしてくださり、恐悦至極に存じます（それなのに筆頭では演題応募せずごめんなさい）
3
195
Soki Kashima retweeted
Tom Powles (@tompowles1) profile picture
Tom Powles
@tompowles1Aug 19
Personalized mRNA-based neoantigen vaccines + pembo are being tested in a number of randomised adjuvant cancer trials (included bladder and renal). The 1st positive trial (RIII in melanoma) was announced today. PCVs are logistically complex with limited monotherapy activity in advanced disease, but early IO combinations in MRD may overcome tumor microenvironment resistance. Patient selection or even vaccine generation could occur with ctDNA. @OncoAlert merck.com/news/merck-and-mod…
Image from Tom Powles (@tompowles1)
7
39
5
157
22,106
Soki Kashima retweeted
Stef Schwartz (@stfshwrtz) profile picture
Stef Schwartz@stfshwrtzAug 12
I’m excited to ride in my 2nd #CloserToFree on Sept. 19! As a Yale PhD student, YCC has supported my training and kidney cancer research in @BraunMDPhD’s lab. I’m proud to help raise funds for patients & families at Smilow and cancer research. 🚴‍♀️ rideclosertofree.org/partici…
A fundraising page for Stephanie Schwartz

A fundraising page for Stephanie Schwartz

Join the Closer to Free Ride on Saturday, September 19th. Register or donate at RideCloserToFree.org.

rideclosertofree.org
3
3
122
ベルズチファン（ウェルレグ）副作用の「貧血」と「低酸素」どちらが厄介？#癌治療 #がん予防 #がん治療 #癌予防 #癌細胞
1
1
74
My favorite photo of #KCRS26. @tompowles1 & @DrChoueiri - winners in the @kidneycan 5K!
Image from Sumanta K. Pal, MD, FASCO (@montypal)
KidneyCAN (@kidneycan) profile pictureKidneyCAN
@kidneycanJul 24
What better way to start Day 2 than by crossing the starting line together? This morning, #KCRS26 attendees laced up for #RockTheRun, a fun tradition that reminds us that every step, whether on the course or in the lab, helps move #KidneyCancer research forward. Thank you to everyone who ran, walked, volunteered, donated, and cheered us on. Together, we're making progress one step at a time. There’s still time to donate: bit.ly/RocktheRun26 #AcceleratingCures
Image from KidneyCAN (@kidneycan)
Image from KidneyCAN (@kidneycan)
Image from KidneyCAN (@kidneycan)
Image from KidneyCAN (@kidneycan)
2
9
68
5,429
Soki Kashima retweeted
Toni Choueiri, MD (@DrChoueiri) profile picture
Toni Choueiri, MD
@DrChoueiriJul 23
Congrats @ZiadBakouny and @BraunMDPhD for this @kidneycan #KCRS26 award!
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
1
14
1
52
5,609
Soki Kashima retweeted
Tom Powles (@tompowles1) profile picture
Tom Powles
@tompowles1Jul 23
Toni Choueiri @DrChoueiri receiving the lifetime achievement award #KCRS26 . Leading a plethora of practice changing trials from METEOR to LITESPARK. >900 publications. Amazing achievement and well deserved.
Image from Tom Powles (@tompowles1)
14
31
8
198
17,333
Soki Kashima retweeted
Fumihiko Urabe (@F_Urabe) profile picture
Fumihiko Urabe@F_UrabeJul 15
🎉 Excited to share that our paper on single-cell RNA sequencing of Hunner-type interstitial cystitis has been published in iScience! 🚀 We identified a previously unrecognized cell population. Thank you so much to everyone who made this work possible!🙌 doi.org/10.1016/j.isci.2026.…
2
14
1,389
Soki Kashima retweeted
YotarOchi (@yota_ochi) profile picture
YotarOchi@yota_ochiJul 8
筆頭論文がNature誌@Natureに掲載されました！ 1563例の急性骨髄性白血病(AML)でクロマチン解析を行い、遺伝子変異だけでなく、エピゲノムの変化も白血病の発症メカニズムや個性を理解する上で重要であることを示した世界初の大規模研究です。(1/10) nature.com/articles/s41586-0…
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia

Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia

Nature - An ATAC-seq-based approach is used to classify acute myeloid leukaemia (AML) into 16 epigenomic subgroups, and provides insight into the role of non-genetic mechanisms in determining...

nature.com
12
112
14
736
186,860
本気の研究が揃い踏みです😮 横浜市大泌尿器科　軸屋良介先生によるHLRCCのmulti-Omics解析の研究を紹介します #JSRC26 @jsrc_1991
11
1
28
11,119
Load more